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Leukotrienes are potent mediators of local microvascular environment. Leukotriene B, treatment of cultured endothe- 
hum increases the binding of lymphocytes to endothelial cell monolayers within minutes. This effect is dose-dependent 
and reversible upon removal of the leukotriene. Pretreatment of lymphocytes slightly decreases the binding and pretreat- 
ment of both lymphocytes and endothelium with leukotriene B4 prior to the adherence assay did not alter the binding. 
These results suggest that leukotriene B4 regulates exclusively the vascular side, but not the white cell side of this interac- 
tion. 
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1. INTRODUCTION 
Leukotrienes B4, C4 and D4 (LTB4, LTG, 
LTD4) all augment vasopermeability after in- 
tradermal injection in both humans and other 
animals [ 1,2]. LTB4 increases granulocyte 
adherence to the microvascular endothelium in the 
hamster cheek pouch [3,4], and granulocyte ex- 
travasation after intradermal injection [2,5]. In- 
creased adherence of granulocytes has been 
demonstrated after in vitro treatment of en- 
dothelial cell monolayers with LTB4 [6]. 
Allograft rejection is most likely regulated at the 
level of the microvascular endothelial cells (EC), as 
this is the site of entry of inflammatory white cells 
into the graft [7]. During the initial phase of rejec- 
tion, the allograft is infiltrated predominantly by 
lymphocytes and monocytes [8]. Since LTB4 in- 
creases granulocyte adhesion to EC monolayers in 
vitro, we tested the effect of LTB4 on the 
lymphocyte-EC interaction. 
Incubation of EC with LTB4 increased lym- 
phocyte binding to EC in a dose-dependent man- 
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ner. The effect was very rapid, and reversible after 
removal of the leukotriene. On the other hand, the 
LTB4 incubation of lymphocytes slightly decreased 
the binding, and if both the cell types were LTB4 
treated no alteration in the binding was seen. 
2. MATERIALS AND METHODS 
2.1. Isolation and culture of endothelial cells 
4-IO-day-old DA rat hearts were minced with a scalpel and 
incubated three times in serum-free MEM with 0.2 mg/ml of 
DNase (600 lU/mg, Sigma, St. Louis) and 0.2 mg/ml of col- 
lagenase (183 U/mg, Worthington). After the first incubation 
(10 min at 37”C, magnetic stirring) the supernatant was 
discarded. Two more 15min incubations were performed and 
the supernatants were collected and filtered through a 50pm 
steel mesh. The red blood cells were lysed with lysing reagent 
for 5 min in 37°C followed by two washings with MEM. The 
single cells were plated in T-25 tissue culture flasks. After 
90 min incubation the non-attached myocardial cells were 
discarded and the highly adherent endothelial cells were left in 
the flask. Endothelial cells usually grew to confluence in 5 days 
and the cells were used at 2-4 passages. 
2.2. Preparation of lymphocytes 
8-IO-week-old DA rat spleens were isolated, a single cell 
suspension was made mechanically and clumps were sedimented 
for 10 min. Red blood cells were lysed with lysing reagent and 
the cells were washed twice with MEM. Approx. 20 x IO6 lym- 
phocytes were suspended in 0.3 ml MEM and 0.3 ml chromium 
was added (containing approx. 300 &i Nazs’Cr04, Amersham 
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International, Amersham, England). After 2 h incubation at 
37°C the cells were washed three times with MEM. Cell viability 
was always greater than 95%. 
2.3. Lymphocyte to EC monolayer adhesion assay 
Endothelial cells were removed from culture flasks with 
versene (I : 5000, Gibco) and trypsin (0. I%, Sigma), centrifuged 
and suspended in MEM at a concentration of 2 x 105/ml. 
0.1-ml aliquots were then cultured overnight in flat-bottomed 
microwell plates (Nun@ precoated with collagen (Gibco). After 
the endothelial monolayer was confirmed with an inverted 
microscope, the EC were washed once, treated with given 
amounts of LTB4 for defined time periods and washed with 
MEM. The “Cr-labelled lymphocytes (IO5 cells in 0.1 ml) were 
added to each microwell. After 60 min incubation at 37”C, 
non-adherent lymphocytes were removed by washing with 
MEM. The bound lymphocytes were lysed by adding 0.1 ml 
Triton X-100 (Sigma) to each microwell and the radioactivity of 
the lysate was measured. The percentage of bound lymphocytes 
was calculated as follows: 
% of bound lymphocytes = 
cpm in the input 
cpm in the lysate 
x 100 
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Fig.1. LTB4 increases lymphocyte binding to endothelial cell 
(EC) monolayers in a dose-dependent manner. LTB4 was added 
population. Data are pooled from 4 different experiments. 
to EC cultures at different concentrations just before 
lymphocytes were added to the assay. Data are expressed as a 
binding index, where binding of lymphocytes to LTBa-treated 
EC is divided by that to untreated EC. Binding of lymphocytes 
to control EC in the absence of LTB4 was 18.2 k 2.2% of input 
Each test was performed as triplicates. Data are expressed as 
a binding index (mean + SD) where the binding of lymphocytes 
with LTBI is divided by the binding of lymphocytes to un- 
treated EC. 
2.4. Reagents 
LTBd was purchased from Upjohn (Michigan, USA). 
3. RESULTS 
In the first experiment LTB4 was added at con- 
centrations of 10-6-10-9 M to the EC culture just 
before plating the “Cr-1abelled lymphocytes onto 
the endothelial cells. With normal, untreated EC, 
the binding of lymphocytes was 18.0 + 2.2% of the 
input population. The addition of LTB4 resulted in 
a dose-dependent increase in lymphocyte binding. 
Maximal effect was observed at 10m8 M LTB4, 
where 33.4 f 3.5% of the input population was 
recovered, leading to a binding index of 1.8 f 0.15 
(fig. 1). 
In the second experiment either endothelial cells 
or lymphocytes were incubated separately with 
LTB4 for 1, 5 or 15 min, washed and added to the 
binding assay. EC pretreatment strongly increased 
the binding with 1 min treatment (binding index 
1.73 f 0.07 at optimal concentration, 10e8 M, of 
LTB4). A similar effect was noted at all time 
periods tested (binding index always above 1.5, 
fig.2). Pretreatment of lymphocytes with LTB4 
slightly decreased the binding on EC (binding in- 
dex 0.84 f 0.14). When both the EC and lym- 
phocytes were pretreated for 5 min with LTB4, 
washed, and tested in a binding assay, the binding 
index amounted to 1.0 f 0.15, i.e. the inhibitory 
effect of LTB4 on lymphocytes overcame the 
enhancing effect of LTB4 on the EC. 
To investigate the duration of the LTB4-induced 
effect, the EC were finally treated with lo-’ M 
LTB4 for 5 min, washed twice with culture 
medium and lymphocytes were added to the assay 
after different time periods. The LTB4-induced, in- 
creased binding capacity of EC decreased 30 min 
after the removal of the leukotriene (binding index 
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Fig.2. Either EC (H), lymphocytes (0). or both cell types (A) 
were pretreated with 10-a M LTB4 for 5 min and washed twice 
before assay. For binding index, see legend to fig. 1. 
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Fig.3. LTB&duced lymphocyte binding effect is reversible 
after removal of the leukotriene. The EC were treated with 
LTB4 (lo-’ M) for 5 mitt, washed twice and lymphocytes were 
added to the culture after indicated time periods. For binding 
index, see legend to fig.1. 
1 Sl f 0.1 vs 1.8 + 0.15) and was totally abolished 
at 60 min (fig.3). 
4. DISCUSSION 
Circulating lymphocytes adhere to specialized 
post-capillary venules of lymphoid tissue (high en- 
dothelial venules), lined by a characteristic ‘high’ 
endothelium [9]. Lymphocytes adhere to the en- 
dothelium only for a few seconds followed either 
by their penetration through the endothelial layer 
into the lymphoid tissue or detachment and con- 
tinuation of circulation [lo]. The in vitro 
lymphocyte-endothelial cell monolayer assay has 
been used extensively in studies of lymphocyte 
migration. Incubation of the EC with y-interferon 
increases the lymphocyte binding significantly 
within days [l 11. Incubation with interleukin 1 in- 
creases the lymphocyte binding within hours [12]. 
Pretreatment of the EC with LTC4 or LTD4 in- 
creases the granulocyte binding within 10 min [ 131, 
as does pretreatment with platelet-activating factor 
(PAF) [13]. 
Our results demonstrate that incubation of EC 
with LTB4 increased lymphocyte binding within 
minutes. LTB4 has also been shown to increase 
granulocyte adherence to EC in vitro [6]. LTB4 
also rapidly increases vascular permeability, 
measured with fluorescence-labelled extran in a 
hamster cheek pouch model [4]. LTB4 possesses 
chemotactic and chemokinetic properties [ 141 and 
it increases leukocyte influx into the skin, when in- 
jected topically intradermally [2]. 
The effect of LTB4 on lymphocyte binding to the 
EC is rapid and transient. EC was incubated with 
an optimal concentration of LTB4, followed by 
washing, and binding was determined after dif- 
ferent time periods. At 30 min there was a signifi- 
cant decrease in the binding and at 60 min the 
increased binding was totally abolished. 
Allograft rejection is characterized by an influx 
of inflammatory white cells into the graft. During 
the first 4 days of drug unmodified rejection, the 
majority of the infiltrating cells are lymphocytes 
and mononuclear phagocytes. Thereafter, when 
necrotic changes become dominant, the number of 
granulocytes also increases [8]. 
Evidence exists that allograft inflammation is 
regulated locally by different potent, short-lived 
mediators, i.e. cytokines and eicosanoids, etc. This 
might explain why, for example combined heart- 
lung transplants are frequently rejected in- 
dependently of each other [15]. Leukotrienes have 
been called ‘pro-rejection’ eicosanoids [ 161. LTB4 
is found in 50-fold greater concentrations in a re- 
jecting kidney allograft cortex [ 171. Inflammatory 
white cells isolated from ‘sponge matrix’ allografts 
produce lo-times more LTB4 than white cells in the 
control sponges [181. Preliminary data suggest hat 
the secretion of LTD4 during rejection into urine 
also increases [ 191. 
The source of LTB4 in the allograft can be either 
inflammatory white cells and/or the graft paren- 
chymal components. Granulocytes, monocytes 
and eosinophiles produce LTB4 [20]. In contrast, 
recently published data demonstrate that highly 
purified human lymphocytes do not produce detec- 
table amounts of any leukotrienes, analysed by 
high-performance liquid chromatography and 
radioimmunoassay techniques [21]. Kidney paren- 
chymal cells including glomerular mesangial and 
epithelial cells as well as tubular cells show cyclox- 
ygenase and 5-lipoxygenase activity [22]. In- 
terleukin 1 stimulus can upregulate at least the 
prostanoid production (PGE2, TxBz and 6-keto 
PGFi,) in mesangial cells [23]. 
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